FdaApplication
BLA 761061
Identifiers
- fda_app_no: BLA761061
Properties
| Property | Value |
|---|---|
| applicant_name | Janssen Biotech, Inc. |
| application_type | BLA |
| approval_date | 2017-07-13 |
Revenue by product
TREMFYA
| Period | Revenue |
|---|---|
| Q2 2026 | $2.0B |
| Q1 2026 | $1.6B |
| Q4 2025 | $1.6B |
| Q3 2025 | $1.4B |
| Q2 2025 | $1.2B |
| Q1 2025 | $956.0M |
| Q4 2024 | $949.0M |
| Q3 2024 | $1.0B |
| Q2 2024 | $906.0M |
| Q1 2024 | $808.0M |
| Q4 2023 | $910.0M |
| Q3 2023 | $891.0M |
| Q2 2023 | $706.0M |
| Q1 2023 | $640.0M |
| Q4 2022 | $752.0M |
| Q3 2022 | $729.0M |
| Q2 2022 | $597.0M |
| Q1 2022 | $590.0M |
| Q4 2021 | $693.0M |
| Q3 2021 | $537.0M |
| Q2 2021 | $479.0M |
| Q1 2021 | $418.0M |
| Q4 2020 | $382.0M |
| Q3 2020 | $327.0M |
| Q2 2020 | $342.0M |
| Q1 2020 | $296.0M |
| Q4 2019 | $270.0M |
| Q3 2019 | $290.0M |
| Q2 2019 | $235.0M |
| Q1 2019 | $217.0M |
| Q4 2018 | $175.0M |
| Q3 2018 | $171.0M |
| Q2 2018 | $126.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
TREMFYA
| Period | Revenue |
|---|---|
| Q2 2026 | $2.0B |
| Q1 2026 | $1.6B |
| Q4 2025 | $1.6B |
| Q3 2025 | $1.4B |
| Q2 2025 | $1.2B |
| Q1 2025 | $956.0M |
| Q4 2024 | $949.0M |
| Q3 2024 | $1.0B |
| Q2 2024 | $906.0M |
| Q1 2024 | $808.0M |
| Q4 2023 | $910.0M |
| Q3 2023 | $891.0M |
| Q2 2023 | $706.0M |
| Q1 2023 | $640.0M |
| Q4 2022 | $752.0M |
| Q3 2022 | $729.0M |
| Q2 2022 | $597.0M |
| Q1 2022 | $590.0M |
| Q4 2021 | $693.0M |
| Q3 2021 | $537.0M |
| Q2 2021 | $479.0M |
| Q1 2021 | $418.0M |
| Q4 2020 | $382.0M |
| Q3 2020 | $327.0M |
| Q2 2020 | $342.0M |
| Q1 2020 | $296.0M |
| Q4 2019 | $270.0M |
| Q3 2019 | $290.0M |
| Q2 2019 | $235.0M |
| Q1 2019 | $217.0M |
| Q4 2018 | $175.0M |
| Q3 2018 | $171.0M |
| Q2 2018 | $126.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (6)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| TREMFYA | GUSELKUMAB | 100MG/ML | Injection |
| TREMFYA | — | 100MG/ML | Injection |
| TREMFYA | — | 200MG/2ML (100MG/ML) | Injection |
| TREMFYA | — | 200MG/2ML (100MG/ML) | Injection |
| TREMFYA | — | 200MG/20ML (10MG/ML) | Injection |
| TREMFYA | — | 100MG/ML | Injection |
6 products